Continuing The Fight.

M2 PRESSWIRE-9 December 2005-Emerging Stock Report: Continuing The Fight.(C)1994-2005 M2 COMMUNICATIONS LTD

RDATE:09122005

Approximately 12 million people are believed to suffer from Sickle Cell Disease worldwide. It is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. People with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body.

The Emerging Stock Report is continuing its coverage on Xechem International, Inc. (OTC BB: XKEM) up 27% today on news that it has acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU), Richmond, VA.

Early research has shown this anti-sickling agent to be a highly effective and relatively non-toxic treatment for Sickle Cell Disease. The new compound further expands Xechem's existing portfolio of products to be used in the fight against Sickle Cell Disease.

Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary focus is on the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases.

The Senate on October 27, 2005 approved an amendment offered by U.S. Senator Thad Cochran and co-sponsored by Senator Jim Talent (R-Mo.), to add $2 million to the Sickle Cell Disease Treatment grant program, created by Senators Talent and Charles Schumer (D-N.Y.), which helps patients suffering from the blood disorder. The Cochran-Talent measure passed unanimously as part of the Labor-HHS Appropriations Act.

"This is a very important amendment which helps reduce health disparities throughout the United States. I can't emphasize enough how much this amendment means to the community of people affected by Sickle Cell Disease not just the 70,000 Americans that have it, not just the 2.5 million Americans who have the trait, but their families and friends who struggle every day with this disease." said Sen. Talent Ian Birrell The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.

Get a Complimentary Subscription at www.emergingstockreport.com Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.

Safe Harbor

All material herein was prepared by the Emerging Stock Report (ESR) www.emergingstockreport.com based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.

ESR' s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements

CONTACT: e-mail: ian@emergingstockreport.com

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data prepared by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).